AAV testing doesn’t have to be a complicated and lengthy process. Expedite your AAV Gene Therapy to market with the most comprehensive set of testing services- all through a single provider.
CBM’s Analytical AcceleratorTM for AAV Testing Platform speeds time to GMP batch release more than three-fold with no wait times and a complete package of platform assays across the full spectrum of FDA quality domains (identity, safety, purity, potency, and stability) located at a single provider.
Analytical development and testing services available regardless of manufacturing source
40+ GMP AAV platform assays available
Up to 50% less sample volume needed by consolidating to a single provider
Custom assay development services leveraging Analytical AcceleratorTM methods; delivered in 6 weeks
0 wait time- Capacity Available Now
Genomic Titer by digital droplet PCR for AAV Vectors containing SV40 polyA signal
Genomic Titer by digital droplet PCR for AAV Vectors using Client Specific Primer and Probes
Genome Copy Titer using qPCR
rAAV Infectious Titer Assay Targeting SV40 ploy A – TCID50 / ddPCR or qPCR
rAAV Infectious Titer Assay Targeting Customer specific targets – TCID50 / ddPCR
Sedimentation Velocity Analysis of Adeno-associated Virus (AAV) using Analytical Ultracentrifugation
Viability and Recovery of Cell Cultures
Protein Concentration using the Micro BCA Protein Assay
Purity by CE-SDS and Capsid Protein Ratio for Adeno-Associated Virus (AAV)
Purity by SDS-Page and Capsid Protein Ratio for Adeno-Associated Virus (AAV)
Aggregation by Size Exclusion Chromatography with Multi Angle Laser Light Scattering (SEC-MALs)
Particle Size by Dynamic Light Scattering Analysis
Adeno-Associated Virus (AAV) Capsid Identity by ELISA
Quantification of Residual Host Cell DNA using qPCR
Quantification of Residual DNA using qPCR Kanamycin Gene
Quantification of Residual DNA using qPCR Ampicillin Gene
Quantification of Residual E1A DNA using qPCR
Quantification of Residual 18s DNA 3 amplicon using qPCR
Quantification of Residual RepCap Plasmid using qPCR
Quantification of Residual Helper Plasmid using qPCR
Residual Host Cell Protein (HEK293) by ELISA
Residual Endonuclease Detection
Residual Bovine Serum Albumin (BSA)
Residual Affinity Ligand by ELISA
Residual Triton X-100 by HPLC
Residual PEI
Replication Competent AAV (rcAAV)
DNA Sequencing by Sanger Sequencing
Determination of pH, USP <791>
Appearance according to the USP <790>
Genomic Identity by Restriction Enzyme Digestion
Osmolality, USP <785>
Sterility Testing, USP/ EP / 21 CFR 610.12 (Direct immersion)
Bacteriostasis and Fungistasis Final Product (Direct immersion)
Endotoxin – USP BET / LAL Kinetic Chromogenic Assay (Endosafe)
Sub-visible particles, USP <788> Particulate Matter Light Obscuration Method (GMP)
USP <697> and EP 2.9.17 Determination of Extractable Volume in Containers (GMP)
Container Closure Testing
Testing for Agar Cultivable and Non-cultivable Mycoplasmas including Mycoplasmastasis (USP/EP)
Mycoplasma Detection by MycoSEQ
In Vitro Assay for Adventitious Virus – 28 day, MRC-5, Vero and HEK-293 cells
Bioburden Testing / Microbial Enumeration
Learn More About Each of Our Capabilities:
Process Development
Analytical Development and Testing
Plasmid DNA Manufacturing
Viral Vector Manufacturing
Cell Therapy Manufacturing
Privacy Policy
Center for Breakthrough Medicines | Copyright 2023